Search Results - "Luggen, M"

Screening for cognitive dysfunction in systemic lupus erythematosus: the Montreal Cognitive Assessment Questionnaire and the Informant Questionnaire on Cognitive Decline in the Elderly by Chalhoub, N.E., Luggen, M.E.

“…Background Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). Traditional…”
Get full text

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy by Genovese, M C, Schiff, M, Luggen, M, Becker, J-C, Aranda, R, Teng, J, Li, T, Schmidely, N, Le Bars, M, Dougados, M

“…To evaluate the safety and efficacy of abatacept during 2 years of the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trial in…”
Get more information

Cognitive dysfunction in SLE: development of a screening tool by Adhikari, T, Piatti, A, Luggen, M

“…Background. Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods…”
Get full text

Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD by Williams, H J, Alarcon, G S, Joks, R, Steen, V D, Bulpitt, K, Clegg, D O, Ziminski, C M, Luggen, M E, St Clair, E W, Willkens, R F, Yarboro, C, Morgan, J G, Egger, M J, Ward, J R

“…(1) To review the diagnoses after 10 years in patients who were identified within 12 months of the onset of well established and undifferentiated connective…”
Get more information

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis by Mould, Diane R., Davis, Charles B., Minthorn, Elisabeth A., Kwok, Deborah C., Elliott, Michael J., Luggen, Michael E., Totoritis, Mark C.

“…Clenoliximab (IDEC‐151) is a macaque‐human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. It…”
Get full text

The evolution of Raynaud's phenomenon: a longterm prospective study by Luggen, M, Belhorn, L, Evans, T, Fitzgerald, O, Spencer-Green, G

“…To evaluate prospectively a cohort of patients with Raynaud's phenomenon (RP) and signs, symptoms, or laboratory abnormalities suggestive of a connective…”
Get more information

Treatment of rheumatic diseases in the elderly by Luggen, Michael

“…Editorial on drug therapy analgesics and nonsteroidal anti-inflammatory drugs, including adverse reactions. [(BNI unique abstract)] 7 references…”
Get full text

Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases by Williams, H J, Alarcón, G S, Neuner, R, Steen, V D, Bulpitt, K, Clegg, D O, Ziminski, C M, Luggen, M E, Polisson, R P, Willkens, R F, Yarboro, C, Morgan, J, Egger, M J, Ward, J R

“…To review the diagnoses after 5 years in patients who were identified within 12 months of the onset of well established and undifferentiated connective tissue…”
Get more information

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition by Genovese, Mark C, Becker, Jean-Claude, Schiff, Michael, Luggen, Michael, Sherrer, Yvonne, Kremer, Joel, Birbara, Charles, Box, Jane, Natarajan, Kannan, Nuamah, Isaac, Li, Tracy, Aranda, Richard, Hagerty, David T, Dougados, Maxime

“…Abatacept is a recombinant fusion protein that modulates T-cell activation. In this trial in patients with rheumatoid arthritis who had an inadequate response…”
Get full text

Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease by Alarcón, G S, Williams, G V, Singer, J Z, Steen, V D, Clegg, D O, Paulus, H E, Billingsley, L M, Luggen, M E, Polisson, R P, Willkens, R F

“…We identified a cohort of 410 patients with connective tissue disorders (CTD) of less than or equal to 1 year duration among the participating clinics of the…”
Get more information

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial by Weinblatt, Michael, Schiff, Michael, Goldman, Allan, Kremer, Joel, Luggen, Michael, Li, Tracy, Chen, Dalei, Becker, Jean-Claude

“…Objective: To investigate the efficacy and safety of abatacept in combination with etanercept in patients with active rheumatoid arthritis during a 1-year,…”
Get full text

Early undifferentiated connective tissue disease. III: Outcome and prognostic indicators in early scleroderma (systemic sclerosis) by BULPITT, K. J, CLEMENTS, P. J, ALARCON, G. S, LUGGEN, M. E, POLISSON, R. P, WILLKENS, R. F, READING, J. C, WILLIAMS, H. J, WARD, J. R, LACHENBRUCH, P. A, PAULUS, H. E, PETER, J. B, AGOPIAN, M. S, SINGER, J. Z, STEEN, V. D, CLEGG, D. O, ZIMINSKI, C. M

“…To characterize the course of early scleroderma and to delineate prognostic factors present within 1 year of disease onset that might identify patients at high…”
Get full text

Remodeling the pyramid--a concept whose time has not yet come by Hess, E V, Luggen, M E

Get more information

Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases by Clegg, D O, Williams, H J, Singer, J Z, Steen, V D, Schlegel, S, Ziminski, C, Alarcón, G S, Luggen, M E, Polisson, R P, Willkens, R F

“…The presence of antinuclear antibodies (ANA) in the serum is a common finding in various connective tissue disorders, but usefulness of these antibodies in…”
Get more information

Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value by Luggen, M E, Gartside, P S, Hess, E V

“…To determine if any nonsteroidal antiinflammatory drug (NSAID) was superior in the treatment of rheumatoid arthritis, duration of use of each drug was employed…”
Get more information

Morbidity from repetitive knee trauma in carpet and floor layers by Thun, M, Tanaka, S, Smith, A B, Halperin, W E, Lee, S T, Luggen, M E, Hess, E V

“…Carpet layers comprise less than 0.06% of the United States workforce yet they submit 6.2% of compensation claims for traumatic knee inflammation. Their work…”
Get full text

Unusual longevity in primary systemic amyloidosis: a 19-year survivor by Fritz, D A, Luggen, M E, Hess, E V

Get more information

A conceptual framework for technology and innovation management in new technology-based firms (NTBF) by Luggen, M., Tschirky, H.

“…To compete with larger firms, new technology-based firms (NTBF) must develop advantages of flexibility and speed of response. Capitalizing on these advantages…”
Get full text

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial by KREMER, Joel, GENOVESE, Mark, RUDERMAN, Eric, COLEMAN, Patricia, CURTIS, David, KOPP, Elliott, KANTOR, Seth, WEISMAN, Michael, WALTUCK, Jonathan, LINDSLEY, Herbert B, MARKENSON, Joseph, CRAWFORD, Bruce, CANNON, Grant W, FERNANDO, Indra, SIMPSON, Karen, STRAND, Vibeke, CALDWELL, Jacques, CUSH, John, FURST, Daniel E, LUGGEN, Michael, KEYSTONE, Ed, BATHON, Joan, KAVANAUGH, Arthur

“…OBJECTIVE: To obtain additional safety and efficacy data on leflunomide (LEF) treatment in combination with methotrexate (MTX) therapy in an open-label…”
Get full text

Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study by Clegg, D O, Reda, D J, Weisman, M H, Blackburn, W D, Cush, J J, Cannon, G W, Mahowald, M L, Schumacher, Jr, H R, Taylor, T, Budiman-Mak, E, Cohen, M R, Vasey, F B, Luggen, M E, Mejias, E, Silverman, S L, Makkena, R, Alepa, F P, Buxbaum, J, Haakenson, C M, Ward, R H, Manaster, B J, Anderson, R J, Ward, J R, Henderson, W G

“…To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active ankylosing spondylitis (AS) that is not…”
Get more information